Luigino Calzetta

TL;DR: It is only proper to consider that dual bronchodilation is better than a LAMA or a LABA alone, regardless of the drugs used, and a gradient of effectiveness among the currently available LAMA/LABA FDCs is identified.

TL;DR: It is likely that the once‐daily dosing of a bronchodilator would be a significant convenience and probably a compliance‐enhancing advantage, leading to improved overall clinical outcomes.

TL;DR: If a patient suffering from chronic bronchitis presents a documented airway obstruction, NAC should be administered at a dose of ≥1200 mg per day to prevent exacerbations, while if a patient suffers from chronic Bronchitis, but is without airway obstruct, a regular treatment of 600 mg per day seems to be sufficient.

TL;DR: A review of the literature on different inhaler device requirements indicates the availability of robust data on the devices characteristics and factors influencing selection of delivery devices is limited.

TL;DR: Overall, RPL554 was well tolerated, and adverse events were generally mild and of equal frequency between placebo and active treatment groups.